Targeting a new signaling pathway to improve treatment for obesity-related diabetes
Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes
['FUNDING_SBIR_2'] · SENSEION THERAPEUTICS, INC. · NIH-10490426
This study is looking at a new way to help people with Type 2 diabetes by testing a special compound that could improve how their body handles insulin and glucose, which might lead to better blood sugar control and fewer complications.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | SENSEION THERAPEUTICS, INC. (nih funded) |
| Locations | 1 site (SAINT LOUIS, UNITED STATES) |
| Trial ID | NIH-10490426 on ClinicalTrials.gov |
What this research studies
This research investigates a novel ion channel signaling complex called SWELL1, which plays a crucial role in regulating insulin sensitivity and secretion in the body. By using a small molecule modulator, SN-401, the research aims to enhance the function of SWELL1, potentially improving glucose metabolism and insulin response in patients with Type 2 diabetes. The approach includes both laboratory studies and animal models to assess the effectiveness of this treatment in normalizing glucose levels and reducing complications associated with diabetes. Patients may benefit from a new therapeutic option that targets the underlying mechanisms of their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with obesity-related Type 2 diabetes who struggle with insulin sensitivity and glucose management.
Not a fit: Patients who do not have Type 2 diabetes or those with other forms of diabetes unrelated to obesity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that improves insulin sensitivity and glucose control in patients with obesity-induced Type 2 diabetes.
How similar studies have performed: Other research has shown promise in targeting similar signaling pathways for diabetes treatment, indicating potential for success with this novel approach.
Where this research is happening
SAINT LOUIS, UNITED STATES
- SENSEION THERAPEUTICS, INC. — SAINT LOUIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LERNER, DANIEL J — SENSEION THERAPEUTICS, INC.
- Study coordinator: LERNER, DANIEL J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cardiovascular Diseases, cardiovascular disorder